1h Free Analyst Time
The publisher has been monitoring the sickle cell disease treatment market and it is poised to grow by $2.33 bn during 2021-2025, progressing at a CAGR of 11.36% during the forecast period. The report on the sickle cell disease treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of sickle cell disease and the provision of special drug designations.
The sickle cell disease treatment market analysis includes the indication segment and geographical landscape.
The sickle cell disease treatment market is segmented as below:
By Indication
- Sickle cell anemia
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the increase in screening tests on infants as one of the prime reasons driving the sickle cell disease treatment market growth during the next few years.
The report on sickle cell disease treatment market covers the following areas:
- Sickle cell disease treatment market sizing
- Sickle cell disease treatment market forecast
- Sickle cell disease treatment market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading sickle cell disease treatment market vendors that include Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA, Novartis AG, and Pfizer Inc. Also, the sickle cell disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- alue Chain Analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2021
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Five Forces Summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Indication
- Market segments
- Comparison by Indication
- Sickle cell anemia - Market size and forecast 2020-2025
- Sickle beta thalassemia - Market size and forecast 2020-2025
- Others - Market size and forecast 2020-2025
- Market opportunity by Indication
Customer landscape
- Overview
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW- Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
Drivers, Challenges, and Trends
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
- Competitive Scenario
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Addmedica SAS
- Bristol-Myers Squibb Co.
- Chiesi Pharmaceuticals BV
- CRISPR Therapeutics AG
- Emmaus Life Sciences Inc.
- Global Blood Therapeutics Inc.
- GlycoMimetics Inc.
- Medunik USA
- Novartis AG
- Pfizer Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research Methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Indication - Market share 2020-2025 (%)
- Comparison by Indication
- Sickle cell anemia - Market size and forecast 2020-2025 ($ million)
- Sickle cell anemia - Year-over-year growth 2020-2025 (%)
- Sickle beta thalassemia - Market size and forecast 2020-2025 ($ million)
- Sickle beta thalassemia - Year-over-year growth 2020-2025 (%)
- Market opportunity by Indication
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Addmedica SAS - Overview
- Addmedica SAS - Product and service
- Addmedica SAS - Key offerings
- Addmedica SAS - Key customers
- Addmedica SAS - Segment focus
- Bristol-Myers Squibb Co. - Overview
- Bristol-Myers Squibb Co. - Product and service
- Bristol-Myers Squibb Co. - Key offerings
- Bristol-Myers Squibb Co. - Key customers
- Bristol-Myers Squibb Co. - Segment focus
- Chiesi Pharmaceuticals BV - Overview
- Chiesi Pharmaceuticals BV - Product and service
- Chiesi Pharmaceuticals BV - Key offerings
- Chiesi Pharmaceuticals BV - Key customers
- Chiesi Pharmaceuticals BV - Segment focus
- CRISPR Therapeutics AG - Overview
- CRISPR Therapeutics AG - Business segments
- CRISPR Therapeutics AG - Key offerings
- CRISPR Therapeutics AG - Key customers
- CRISPR Therapeutics AG - Segment focus
- Emmaus Life Sciences Inc. - Overview
- Emmaus Life Sciences Inc. - Business segments
- Emmaus Life Sciences Inc. - Key offerings
- Emmaus Life Sciences Inc. - Key customers
- Emmaus Life Sciences Inc. - Segment focus
- Global Blood Therapeutics Inc. - Overview
- Global Blood Therapeutics Inc. - Business segments
- Global Blood Therapeutics Inc. - Key offerings
- Global Blood Therapeutics Inc. - Key customers
- Global Blood Therapeutics Inc. - Segment focus
- GlycoMimetics Inc. - Overview
- GlycoMimetics Inc. - Business segments
- GlycoMimetics Inc. - Key offerings
- GlycoMimetics Inc. - Key customers
- GlycoMimetics Inc. - Segment focus
- Medunik USA - Overview
- Medunik USA - Product and service
- Medunik USA - Key offerings
- Medunik USA - Key customers
- Medunik USA - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global sickle cell disease treatment market: Addmedica SAS, Bristol-Myers Squibb Co., Chiesi Pharmaceuticals BV, CRISPR Therapeutics AG, Emmaus Life Sciences Inc., Global Blood Therapeutics Inc., GlycoMimetics Inc., Medunik USA, Novartis AG, and Pfizer Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increase in screening tests on infants.'
According to the report, one of the major drivers for this market is the high prevalence of sickle cell disease.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Addmedica SAS
- Bristol-Myers Squibb Co.
- Chiesi Pharmaceuticals BV
- CRISPR Therapeutics AG
- Emmaus Life Sciences Inc.
- Global Blood Therapeutics Inc.
- GlycoMimetics Inc.
- Medunik USA
- Novartis AG
- Pfizer Inc.
